There is evidence to suggest that the MAPK pathway may be cardioprotective; BRAF and MEK inhibitors inhibit this pathway and can lead to hypertrophy, apoptosis, cardiac remodeling, and declines in LVEF as well as arterial hypertension via effects on nitric oxide production. The gene discussed is BRAF; the disease is Hypertension.